BPC-157 oral, nasal or injected: what each route has behind it
Reviewed 26 sourcesPublished by PepVault
Every BPC-157 study grouped by route and species: oral, injected, cream, enema and nasal. What each route has shown, and where no study exists at all.

- Last reviewed
- Sources
- 26
- Questions
- 7
- Compounds
- 1
The short answer
Most BPC-157 research is in rats. Swallowed in drinking water or injected into the belly or a muscle, it sped healing in those studies, and studies that gave it both ways found each worked. No study in any species has tested a nasal spray. In people, the published reports used injections into a knee, the bladder wall, the mouth lining or a drip into a vein, plus two enema trials.
Evidence: Animal research for most routes, mostly in rats; in people, four small uncontrolled reports by injection or infusion and two enema trials known only from abstracts; no study of a nasal spray in any species.

Which routes of BPC-157 have been studied, and in what?
A route is the way a compound gets into the body: swallowed, injected, sprayed or rubbed on. BPC-157 has been tested by many routes, almost all of them only in animals, and one popular route not at all. Here is every route, with the species each was studied in.
| Route | Animal studies | People |
|---|---|---|
| By mouth (drinking water, capsule, tablet) | Rats, mice, even honeybees12424 | No published results; a tablet trial and a gummy study are registered2122 |
| Stomach tube (intragastric) | Rats5 | None |
| Into the belly cavity (intraperitoneal) | Rats and mice: most of the healing studies711 | None; a lab route |
| Into a muscle (intramuscular) | Rats, rabbits, dogs568 | None |
| Under the skin (subcutaneous) | Rats, one study of brain chemistry, the only one we found10 | One trial registered, not yet started23 |
| Into a vein (intravenous) | Rats (heart rhythm, bleeding) and dogs (blood levels)826 | 2 healthy adults9 |
| On the skin or eye (cream, eye drops) | Rats and mice171213 | None |
| Into a joint (intra-articular) | None found | 16 people with knee pain, 4 of them also given TB-50017 |
| Into the bladder wall | None found | 12 women with bladder pain18 |
| Into the mouth lining, near a nerve | None found | 3 patients, mixed with four other drugs19 |
| Rectal (enema) | Safety tests in rats and dogs, unpublished20 | Two trials, reported only as meeting abstracts1620 |
| Nasal spray (intranasal) | None | None141516 |

PepVault records each compound's route: under the skin, into a muscle, by mouth or nasal. Swallowed and nasal doses log with one tap, and injections ask for the site, so your log shows what went where. Log it in PepVault
Every animal result below is from rats, mice, rabbits or dogs given amounts per kilogram of body weight. None of it is a dose for a person, and an effect in a rat is not proof of one in people.

PepVault for iPhone
Keep your protocol in PepVault
PepVault records each compound's route: under the skin, into a muscle, by mouth or nasal. Swallowed and nasal doses log with one tap, and injections ask for the site, so your log shows what went where.
7 days free on the yearly plan for new subscribers.
Does BPC-157 work when swallowed?
In rats, yes, over and over. Its developers usually dissolve it in the animals' drinking water, so the rats take it in small sips all day. Given that way, it improved healing of a cut knee ligament over 90 days1, restored a junction between muscle and tendon that was cut in surgery and does not heal on its own2, and closed a leaking channel between the colon and the skin3. In mice, BPC-157 by mouth reduced liver damage from radiation4. Honeybee colonies fed it in sugar syrup grew stronger as their gut-parasite counts fell24.
The reason it can work this way is unusual for a peptide. Most peptides are cut apart by stomach acid and enzymes; BPC-157 comes from a protein in human gastric juice and holds up in it in the lab15. Many of the oral studies are gut models (ulcers, colitis, fistulas), where a swallowed peptide meets the injury directly. The ligament and tendon results are the interesting ones, because there it had to act beyond the gut12.
No published study has measured how much of a swallowed dose reaches the blood. That share is called bioavailability. A 2026 review notes that no one has measured how well it crosses the gut wall15, and the FDA's July 2026 review found no study measuring blood levels after an oral dose in animals or people16; an unpublished 1996 rat study followed a radio-labelled oral dose, but its developers report only where the label went20. In people, a placebo-controlled tablet trial in 42 healthy volunteers was registered in 2015 and has posted no results21; BPC-157’s developers write that no measurable BPC-157 was found in the volunteers' blood or urine20. A study of BPC-157 gummies in 40 active adults, with no comparison group, finished in 2025 with no results posted22.
A stomach tube is the lab's precise version of swallowing: a measured amount goes straight into the stomach. In rats with stomach ulcers it worked, though less well than an injection into muscle5.
Is injecting BPC-157 better than taking it by mouth?
Nobody knows for people, because no human study has compared two routes. Dozens of animal studies, almost all from one group in Zagreb, gave it by more than one route, and they mostly found that each worked. Six examples:
| Study | Species | Routes compared | What they found |
|---|---|---|---|
| Cut knee ligament, 20101 | Rats | Belly injection, drinking water, cream on the injury | All three improved healing through 90 days |
| Muscle-tendon junction, 20212 | Rats | Belly injection, drinking water | Both restored the junction |
| Colon-skin fistula, 20083 | Rats | Belly injection, drinking water | Both closed the fistula |
| Stomach ulcers, 20045 | Rats | Muscle injection, stomach tube | Both shrank ulcers; the muscle injection worked better and at a lower dose |
| Bone gap, 19996 | Rabbits | Injection into the gap, muscle injection | Both healed more gaps than in untreated rabbits |
| Burns, 20017 | Mice | Cream on the burn, belly injection | Both helped; the cream improved every healing measure |

Only one of the six, the stomach ulcer study from a lab in China, ranked one route above another5. The other five come from the Zagreb group that discovered BPC-157 or its hospital partners, and they show it working by several routes rather than ranking them.
The injected numbers that do exist come from a 2022 study in rats and beagle dogs. Given into a vein or a muscle, half of it was gone in under 30 minutes (its half-life), broken down into fragments and ordinary amino acids. Injected into muscle, about 14 to 19% reached the blood in rats and 45 to 51% in dogs8. Nothing similar exists for injection under the skin16, and the only rat study we found by that route measured brain serotonin, not healing10.
Most of the injection studies use the belly cavity, the space around the gut (intraperitoneal injection), as the tendon studies did211. It is a standard lab route because it is quick in small animals, but it is not a route used in people, so the closest human route has much less behind it.
When to get help If an injection site turns hot, swollen and more painful each day, or you get a fever, see a doctor.
Is there any research on BPC-157 nasal spray?
None, in any species. The one PubMed paper that pairs BPC-157 with the nose is a 1997 rat study in which the irritant capsaicin went into the nose and BPC-157 was injected into the belly; it reduced the inflammatory cells in the nasal lining14. The peptide itself never went up the nose.
A 2026 review of BPC-157 as a drug states it plainly: no preclinical or clinical data exist for intranasal BPC-15715. The FDA's 2026 review agrees and lists the nasal route's blood levels as unknown16. The same review adds a general point about peptides: given under the skin or into the nose, they are more likely to set off an immune response, the body making antibodies against them, than when swallowed or given rectally. No study has tested BPC-157 for this by any route16.
So a nasal spray is the route with the least behind it: no animal result, no blood level, no human report.
Does BPC-157 cream or eye drops do anything?
On broken skin in animals, yes. A cream laid on the injury helped a cut knee ligament heal in rats1, creams sped the healing of deep burns in mice7, and a treatment put on alkali burns in rats closed wounds faster, with more collagen in the healed skin12. As eye drops, it closed a cut through the cornea, the clear front of the eye, within three to four days in rats, while eyes given plain water healed poorly13.
Every one of those went onto a wound or a burn, where the skin's barrier was already open. Intact skin is another matter. At 1,419 daltons, a measure of molecular size, BPC-157 is almost three times the roughly 500 daltons that pass through healthy skin easily, so a 2026 review expects plain creams to do little without help getting through15. No study has tested a BPC-157 cream in people.
Which routes have been tried in people?
Four small reports have been published, none with a comparison group, and two enema trials are known from meeting abstracts. A 2026 systematic review counted three of the reports (the knee, bladder and vein studies), 30 people in total, and rated the certainty of the evidence very low25.
- Into a joint: 16 patients with knee pain, asked by phone months later; 14 said the pain eased; 4 had also been given TB-50017.
- Into the bladder wall: 12 women with interstitial cystitis, injected during one camera exam of the bladder; 10 reported their symptoms gone18.
- Into a vein: 2 healthy adults, with no change in heart, liver, kidney, thyroid or blood sugar markers9.
- Into the mouth lining: 3 dental patients with nerve injury, given BPC-157 together with TB-500, ARA-290 and two other drugs, so its share cannot be separated19.
- Enema: a phase I trial in 32 healthy men and a placebo-controlled trial in 53 people with ulcerative colitis, known only from meeting abstracts; BPC-157 was mostly or entirely undetectable in their blood1620.
What is missing is as telling. No published study has given it to people by mouth, under the skin, through the skin or as a nasal spray16. The first controlled trial by injection under the skin, after shoulder surgery at the University of Arkansas, is set to start in January 202723. Our guide at pepvault.app/guides/bpc-157-human-data goes through each of these studies in detail.
What do people who use it report?
Commonly reported: faster recovery from tendon and ligament injuries, with pain easing within one to three weeks, and a calmer gut, with less reflux or bloating, especially when it is taken by mouth.
These are user reports, not study results; only the animal studies have put the routes side by side. How soon users say it starts to work is at pepvault.app/peptides/bpc-157/how-long-to-work, and the compound’s full page is pepvault.app/peptides/bpc-157.
Sources
- Cerovecki T et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010. PubMed 20225319
- Japjec M et al. Stable gastric pentadecapeptide BPC 157 as a therapy for the disable myotendinous junctions in rats. Biomedicines. 2021. PubMed 34829776
- Klicek R et al. Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats. J Pharmacol Sci. 2008. PubMed 18818478
- Huang BS et al. Pentadecapeptide BPC 157 efficiently reduces radiation-induced liver injury and lipid accumulation through Kruppel-like factor 4 upregulation both in vivo and in vitro. Life Sci. 2022. PubMed 36228773
- Xue XC et al. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World J Gastroenterol. 2004. PubMed 15052688
- Sebecic B et al. Osteogenic effect of a gastric pentadecapeptide, BPC-157, on the healing of segmental bone defect in rabbits. Bone. 1999. PubMed 10071911
- Mikus D et al. Pentadecapeptide BPC 157 cream improves burn-wound healing and attenuates burn-gastric lesions in mice. Burns. 2001. PubMed 11718984
- He L et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022. PubMed 36588717
- Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025. PubMed 40131143
- Tohyama Y, Sikiric P, Diksic M. Effects of pentadecapeptide BPC157 on regional serotonin synthesis in the rat brain. Life Sci. 2004. PubMed 15531385
- Staresinic M et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003. PubMed 14554208
- Huang T et al. Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro. Drug Des Devel Ther. 2015. PubMed 25995620
- Masnec S et al. Perforating corneal injury in rat and pentadecapeptide BPC 157. Exp Eye Res. 2015. PubMed 25912999
- Kalogjera L et al. Dose-dependent protective effect of BPC 157 on capsaicin-induced rhinitis in rats. Eur Arch Otorhinolaryngol. 1997. PubMed 9065615
- Mateescu DM et al. BPC-157 as an investigational peptide therapeutic: biopharmaceutical challenges, formulation strategies, and translational development barriers. Pharmaceutics. 2026. PubMed 42198317
- U.S. Food and Drug Administration. Briefing document for BPC-157-related bulk drug substances, Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026. fda.gov
- Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021. PubMed 34324435
- Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. 2024. PubMed 39325560
- Froum S et al. Case report: regenerative peptides for inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases. Front Oral Health. 2026. PubMed 42876687
- Sikiric P et al. Stable gastric pentadecapeptide BPC 157 as a therapy and safety key: a special beneficial pleiotropic effect controlling and modulating angiogenesis and the NO-system. Pharmaceuticals (Basel). 2025. PubMed 40573323
- ClinicalTrials.gov NCT02637284. PCO-02: safety and pharmacokinetics trial. PharmaCotherapia. clinicaltrials.gov
- ClinicalTrials.gov NCT07752381. A clinical trial to evaluate the effects of peptide gummies on markers of inflammation, physical performance, and recovery. clinicaltrials.gov
- ClinicalTrials.gov NCT07803250. Impact of BPC-157 on recovery following rotator cuff repair surgery. University of Arkansas. clinicaltrials.gov
- Tlak Gajger I et al. Stable gastric pentadecapeptide BPC 157 in honeybee (Apis mellifera) therapy, to control Nosema ceranae invasions in apiary conditions. J Vet Pharmacol Ther. 2018. PubMed 29682749
- Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg. 2026. PubMed 42885452
- Balenovic D et al. Inhibition of methyldigoxin-induced arrhythmias by pentadecapeptide BPC 157: a relation with NO-system. Regul Pept. 2009. PubMed 19465062
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.